Related Experiment Video

Updated: Apr 14, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

7.0K

Novel anti-inflammatory therapies for the treatment of atherosclerosis

Razi Khan1, Vincent Spagnoli1, Jean-Claude Tardif1

  • 1Department of Medicine, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.

Atherosclerosis
|April 29, 2015
PubMed

Insights

Inflammation drives atherosclerosis, but current treatments for coronary artery disease (CAD) focus on lipids, not inflammation. Novel anti-inflammatory therapies targeting pathways like interleukin-1β (IL-1β) show promise for CAD treatment.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacology

Background:

  • Inflammation plays a key role in atherosclerosis and coronary artery disease (CAD).
  • Current CAD treatments primarily target serum lipoprotein levels, neglecting inflammation's detrimental effects.
  • Vascular inflammation involves complex molecular and cellular pathways contributing to atherogenesis.

Purpose of the Study:

  • To review emerging anti-inflammatory therapies for CAD.
  • To highlight novel pharmacotherapies targeting specific inflammatory pathways.
  • To examine the evidence for these treatments in experimental and clinical settings.

Main Methods:

  • Review of basic studies and clinical trials on anti-inflammatory treatments for CAD.
  • Focus on therapies targeting interleukin-1β (IL-1β), P-selectin, and 5-lipoxygenase (5-LO).
  • Examination of serpin administration, colchicine, and HDL-directed treatments.

Main Results:

  • Evidence supports the potential benefits of treating inflammation in CAD.
  • Accelerated development of pharmacotherapies targeting inflammation in atherosclerosis.
  • Mechanistic rationale and experimental/clinical data for novel anti-inflammatory agents.

Conclusions:

  • Targeting vascular inflammation represents a promising therapeutic strategy for CAD.
  • Novel agents offer new avenues beyond traditional lipid-lowering therapies.
  • Further clinical evaluation of these anti-inflammatory treatments is warranted.
Keywords:
5-LipoxygenaseColchicineInterleukin-1βIntravenous HDLP-SelectinSerpin

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.9K
A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

9.4K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
616
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
986
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
716
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
666